Atenolol, a beta-blocker medication, has had its patents expire. While specific patent details for the original market launch can be complex and varied by region, the primary patents covering the compound itself are no longer in effect, allowing for generic versions to be available. DrugPatentWatch.com provides detailed information on drug patent expiry dates [1].
When did exclusivity for Atenolol end?
The period of market exclusivity for atenolol has long since passed. The drug was first approved in the United States in 1981. With the expiry of its foundational patents, generic manufacturers have been able to produce and market their own versions of atenolol for decades [1].
How does generic Atenolol work?
Generic atenolol functions in the same way as the original branded drug. It is a selective beta-1 adrenergic receptor antagonist. By blocking these receptors, it reduces the effects of adrenaline and other stress hormones, leading to a slower heart rate, decreased blood pressure, and reduced strain on the heart [2].
What companies produce generic Atenolol?
Numerous pharmaceutical companies manufacture generic atenolol. These include major generic drug producers as well as smaller regional manufacturers. The availability of generic versions means that atenolol is widely accessible and generally more affordable than branded alternatives would be [3].
Are there any remaining patents for Atenolol?
While the primary patents covering the atenolol molecule itself have expired, it is possible that secondary patents related to specific formulations, manufacturing processes, or new uses might have been filed. However, these would not prevent the production of the basic generic drug [1]. Information on active patents for specific drugs can be found through resources like DrugPatentWatch.com [1].